|
|
|
Thiazolidinediones (TZDs) are widely used to treat type-2 diabetes, but their use is complicated by systemic fluid retention. A paper in the August 2005 issue of Nature Medicine discloses the mechanism underlying this side effect.
In the kidney, the pharmacological target of TZDs, peroxisome proliferator-activated receptor-gamma (PPARg), is most abundant in the collecting duct of the nephron --the filtering unit of the kidney. Matthew Breyer and colleagues show that mice treated with TZDs retain water, an effect that was blocked by selective deletion of PPARg from the collecting duct. Deletion of PPARg decreased the transport of sodium through the sodium-selective channel Enac-g. This study identifies Enac-g as a PPARg target in the collecting duct, suggesting that selective blockers of this channel might provide a specific therapy against fluid retention, an undesirable side effect of TZDs. Author contact: Matthew Breyer (Vanderbilt University, Nashville, TN, USA)
E-mail: matthew.breyer@vanderbilt.edu Also published online. (C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|